Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

References
1 Hall, S. S. A commotion in the blood:
Life, death, and the immune system.
Sloan Technology Series 1997; Henry
Holland Company, New York.
2 Coley,W. B. The treatment of malignant
tumors by repeated inoculations
of erysipelas: with a report of ten original
cases. Am J Med Sci 1893; 105: 487±
511.
3 Wiemann, B. and Starnes, C. O. Coley's
toxins, tumor necrosis factor and
cancer research: a historical perspective.
Pharmacol Ther 1994; 64: 529±564.
4 Bast, R. C., Jr, Zbar, B., Borsos, T. and
Rapp, H. J. BCG and cancer. N Engl J
Med 1974; 290: 1458±1469.
5 Morales, A. Adjuvant immunotherapy
in superficial bladder cancer. Natl Cancer
Inst Monogr 1978; 49: 315±319.
6 Tokunaga, T.,Yamamoto, H., Shimada,
S., et al. Antitumor activity of
deoxyribonucleic acid fraction from Mycobacterium
bovis BCG. I. Isolation, physicochemical
characterization, and antitumor
activity. J Natl Cancer Inst 1984;
72: 955±962.
7 Yamamoto, S., Kuramoto, E., Shimada,
S. and Tokunaga, T. In vitro augmentation
of natural killer cell activity
and production of interferon-a/b and -g
with deoxyribonucleic acid fraction
from Mycobacterium bovis BCG. Jpn J
Cancer Res 1988; 79: 866±873.
8 Tokunaga, T.,Yamamoto, T. andYamamoto,
S. How BCG led to the discovery
of immunostimulatory DNA. Jpn J Infect
Dis 1999; 52: 1±11.
9 Yamamoto, S.,Yamamoto, T., Shimada,
S., et al. DNA from bacteria, but
not from vertebrates, induces interferons,
activates natural killer cells and inhibits
tumor growth. Microbiol Immunol
1992; 36: 983±997.
10 Kuramoto, E.,Yano, O., Kimura,Y.,
et al. Oligonucleotide sequences required
for natural killer cell activation.
Jpn J Cancer Res 1992; 83: 1128±1131.
11 Messina, J. P., Gilkeson, G. S. and
Pisetsky, D. S. Stimulation of in vitro
murine lymphocyte proliferation by
References
bacterial DNA. J Immunol 1991; 147:
1759±1764.
12 Messina, J. P., Gilkeson, G. S. and
Pisetsky, D. S. The influence of DNA
structure on the in vitro stimulation of
murine lymphocytes by natural and
synthetic polynucleotide antigens. Cell
Immunol 1993; 147: 148±157.
13 Jacobs, B. L. and Langland, J. O.
When two strands are better than one:
the mediators and modulators of the
cellular responses to double-stranded
RNA. Virology 1996; 219: 339±349.
14 Talmadge, J. E., Adams, J., Phillips, H.,
et al. Immunomodulatory effects in
mice of polyinosinic±polycytidylic acid
complexed with poly-l-lysine and carboxymethylcellulose.
Cancer Res 1985; 45:
1058±1065.
15 Manetti, R., Annunziato, F., Tomasevic,
L., et al. Polyinosinic acid: polycytidylic
acid promotes T helper type 1specific
immune responses by stimulating
macrophage production of interferon-a
and interleukin-12. Eur J Immunol
1995; 25: 2656±2660.
16 Kern, E. R., Overall, J. C., Jr and
Glasgow, L. A. Herpesvirus hominis
infection in newborn mice: treatment
with interferon inducer polyinosinicpolycytidylic
acid. Antimicrob Ag Chemother
1975; 7: 793±800.
17 Levy, H. B., London,W., Fuccillo,
D. A., Baron, S. and Rice, J. Prophylactic
control of simian hemorrhagic fever
in monkeys by an interferon inducer,
polyriboinosinic±polyribocytidylic acidpoly-l-lysine.
J Infect Dis 1976; 133
(Suppl.): A256±A259.
18 Harrington, D. G., Crabbs, C. L., Hilmas,
D. E., et al. Adjuvant effects of low
doses of a nuclease-resistant derivative
of polyinosinic acid.polycytidylic acid
on antibody responses of monkeys to
inactivated Venezuelan equine encephalomyelitis
virus vaccine. Infect Immun
1979; 24: 160±166.
19 Levine, A. S. and Levy, H. B. Phase I±
II trials of poly IC stabilized with poly-llysine.
Cancer Treat Rep 1978; 62: 1907±
1912.
279